CRISPR Therapeutics AG (CRSP) Revenue (2016 - 2026)

CRISPR Therapeutics AG has disclosed Revenue across 11 years of filings, most recently posting $10.2 million for Q2 2026.

• In Q2 2026, Revenue rose 1041.37% year-over-year to $10.2 million; the TTM figure through Jun 2026 stood at $13.4 million (down 64.8% YoY), while the FY2025 annual figure was $3.5 million, down 90.59% from the prior year.
• Revenue came in at $10.2 million for Q2 2026 at CRISPR Therapeutics AG, up from $1.5 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $201.2 million in Q4 2023 to a low of $6000.0 in Q4 2022.
• Average Revenue over 5 years is $25.0 million, with a median of $889000.0 recorded in 2025.
• Year-over-year, Revenue plunged 99.98% in 2022 and jumped 3353333.33% in 2023.
• Over 5 years, Revenue stood at $6000.0 in 2022, then jumped by 3353333.33% to $201.2 million in 2023, then plunged by 82.26% to $35.7 million in 2024, then sank by 97.58% to $864000.0 in 2025, then jumped by 1078.36% to $10.2 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $10.2 million in Q2 2026, $1.5 million in Q1 2026, and $864000.0 in Q4 2025.